Introduction
============

Prostate cancer (PCa) is the most common malignant tumor and the second leading cause of cancer-associated mortality among men in the Western world ([@b1-ol-0-0-11830]). In 2015, 60,300 new cases of PCa were diagnosed in China, leading to 26,000 mortalities ([@b2-ol-0-0-11830]). In patients treated with radical prostatectomy (RP) or radiation therapy for localized PCa, biochemical recurrence (BCR) is defined as two consecutive prostate-specific antigen (PSA) values ≥0.2 ng/ml after RP, or a PSA level ≥2.0 ng/ml above the nadir after external beam radiation therapy or brachytherapy ([@b3-ol-0-0-11830]). The rate of BCR following RP has been estimated to be 20--40% ([@b4-ol-0-0-11830]). In the absence of secondary treatment, patients with BCR have an approximate median period of 5--8 years prior to clinical progression; among these, 32--45% will succumb to PCa within 15 years ([@b5-ol-0-0-11830]).

In order to facilitate BCR assessment, evaluate prognosis and individualize patient follow-up, it is critical to identify patients with a high-risk of BCR following RP. However, the current risk stratification methods, which are mainly based on clinicopathological parameters, only partially address the observed variation in clinical outcomes and are not accurate enough to predict high-risk BCR ([@b6-ol-0-0-11830]). With the development of next-generation sequencing, several genomic biomarkers have been identified and used as prognostic factors and predictive signatures ([@b7-ol-0-0-11830],[@b8-ol-0-0-11830]).

The Gleason system was developed by Donald Gleason between 1966--1974 and was used to evaluate the degree of malignance of PCa ([@b9-ol-0-0-11830]). In previous years, multiple studies have described that PCa with a Gleason score (GS) of 6 is unable to metastasize or cause cancer-associated mortality, in addition to having a low risk rate for BCR after RP ([@b10-ol-0-0-11830]--[@b12-ol-0-0-11830]). Although patients with GS ≥7 are at a much higher risk for disease progression compared with patients with GS=6, even patients with GS ≥8 can experience favorable oncological outcomes, such as BCR risk and survival time, which highlights the heterogeneity of PCa ([@b13-ol-0-0-11830],[@b14-ol-0-0-11830]). Furthermore, patients with GS 3+4 PCa have similar outcomes compared with patients with GS=6 ([@b15-ol-0-0-11830]). Therefore, it was hypothesized that the genomic features of GS=6 PCa, which may also be shared with GS ≥7 PCa, could be harnessed to further stratify PCa into conventional, intermediate and high-risk PCa.

The aim of the present study was to identify differentially expressed genes (DEGs) between patients with PCa and GS=6 and GS ≥7, using The Cancer Genome Atlas (TCGA) data. These DEGs were used to construct and validate an PCa signature (PCasig) that could identify patients with a high-risk of BCR using Cox regression analysis. In addition, the present study aimed to analyze the biological signaling pathway associated with the PCasig using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Lastly, the endogenous expression of the genes identified in the PCasig was determined in PCa and normal prostate cell lines.

Materials and methods
=====================

### Data preparation and processing

A flowchart of the analysis conducted in the present study is shown in [Fig. 1](#f1-ol-0-0-11830){ref-type="fig"}. High-throughput RNA sequencing (RNA-seq) data, with RNA-seq data (HTSeq-Counts) and corresponding clinicopathological parameters of patients with PCa after RP were obtained from TCGA (<https://tcga-data.nci.nih.gov/tcga/>), and served as the discovery cohort (TCGA-PRAD). Taylor Prostate 3, another gene expression array of human PCa datasets, was obtained from Oncomine (<https://www.oncomine.org/resource/login.html>) and served as the validation cohort. The inclusion criteria were as follows: i) Pathologically confirmed diagnosis of prostate adenocarcinoma; ii) complete record of clinicopathological parameters, including follow-up time, age, GS, pathological T and N stage, clinical M stage, situation of residual tumor, and time to BCR; and iii) RNA-seq data. The exclusion criteria were as follows: i) Pathologic result was not prostate adenocarcinoma; ii) missing clinicopathological parameters, including follow-up time, age, GS, pathological T and N stage, clinical M stage ([@b16-ol-0-0-11830]), situation of residual tumor, and time to BCR; and iii) no RNA-seq data.

A total of 414 patients with both RNA-seq data and corresponding clinicopathological information were included in the discovery cohort and 377 of them had a GS ≥7. The median age of patients in the discovery cohort was 61 years (age range, 41--78 years). A total of 138 patients with RNA-seq data and corresponding clinicopathological parameters were included in the validation cohort, and 97 of them had a GS ≥7. The median age of patients in the validation cohort was 58 years (age range, 37--73 years).

### Development and validation of the PCasig

The DEGs in GS=6 and GS ≥7 PCa were analyzed in the discovery cohort using the edgeR package (version 3.30.0; <http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>) in R software (version 3.5.2; <http://www.r-project.org>), with \|log2 \[fold change (FC)\]\|\>1.0 and a false discovery rate of 0.05 used as the threshold values. The significant DEGs were considered to be candidate genes for further analysis.

The RNA-seq data were normalized using the transcripts per million (TPM) method and a log2-based transformation (log~2~TPM) for further survival analysis. Univariate Cox proportional hazards (PH) regression analysis was used to analyze the association between the expression levels of the DEGs and time to BCR in patients with GS ≥7. P\<0.05 was considered to indicate a statistically significant difference. The least absolute shrinkage and selection operator (LASSO) method was utilized to screen significant DEGs and to avoid overfitting the model. The LASSO method can effectively solve the computational difficulties of estimation in high-dimensional and low-sample size environments ([@b17-ol-0-0-11830]).

Based on the results of the LASSO analysis, multivariate Cox analysis was performed to identify a PCasig and calculate the risk score of each patient, using weighted estimators corresponding to each gene expression level. All patients were divided into low and high score groups according to the median risk score. Kaplan-Meier curves and a log-rank test were used to assess the prognostic effect of the prognosis risk score. The PCasig was applied to the validation cohort to determine whether it could discriminate high-risk BCR patients. PCasig performance was assessed by time-dependent receiver operating characteristic (ROC) curve analysis within 3 and 5 years, and the concordance index (C-index).

In the present study, the 'survival' package was installed for the R software version 3.5.2 (R Core Team; <http://www.R-project.org/>). The 'survival' package (v3.1--12; <http://cran.r-project.org/web/packages/survival/index.html>) was used to perform Cox regression analysis. In addition, the following packages were used: i) 'glmnet' for LASSO Cox analysis (version 4.0; <http://cran.r-project.org/web/packages/glmnet/index.html>); ii) 'survminer' for survival curves (v0.4.7; <http://cran.r-project.org/web/packages/survminer/index.html>); iii) 'survival ROC' to obtain the area under the curve (AUC) (v1.0.3; <http://cran.r-project.org/web/packages/survivalROC/index.html>); and i) 'rms' to calculate the C-index (v5.1--4; <http://cran.r-project.org/web/packages/rms/>).

### Association and comparison of the PCasig with the clinicopathological parameters

Univariate and multivariate analysis using Cox regression models was conducted in the discovery cohort to test the prognostic effect of each parameter and their dependencies. The present study compared the prognostic performance of the PCasig against the clinical nomogram constructed using clinicopathological parameters with respect to time to BCR. P\<0.05 was considered to indicate a statistically significant difference.

### Incremental predictive value of the PCasig for the clinical nomogram

In order to evaluate whether the PCasig could improve the predictive performance, a new nomogram was constructed, by adding the PCasig into the clinical nomogram, as a prognostic factor. Therefore, the incremental value of the PCasig as an additional candidate predictor was evaluated, the AUC and the calibration curve were derived, and the net reclassification improvement (NRI) was calculated using 'nricens' package (version 1.6; <http://cran.r-project.org/web/packages/nricens/>) ([@b18-ol-0-0-11830]).

### Prognostic effect of the PCasig in different GS subgroups

The present study also evaluated whether the PCasig was a significant predictor of BCR compared with other clinicopathological parameters in different GS subgroups. Cox regression and Kaplan-Meier curve analyses were performed in the GS=7 and GS ≥8 subgroups.

### Functional enrichment analysis

GO and KEGG pathway enrichment analysis of PCasig were performed using the 'cluster profiler' package (version 3.16.0; <http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html>) to examine the GO terms and pathways. P\<0.05 was considered to indicate a statistically significant enrichment.

### Cell lines and culture

Human PCa cell lines (PC-3, DU145, 22RV1, C4-2 and LNCaP) were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. All the PCa cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (cat. no. 10099; Gibco, Thermo Fisher Scientific, Inc.). Normal prostatic epithelial cells RWPE-1 were purchased from the American Type Culture Collection and cultured in Keratinocyte Serum Free Medium (cat. no. 10744-019) supplemented with 5 ng/ml epidermal growth factor (cat. no. 10450-013) and 1% penicillin/streptomycin (cat. no. 15140-122; all purchased from Gibco; Thermo Fisher Scientific, Inc.). All cells were incubated at 37°C in 5% CO~2~.

### RNA extraction and RT-quantitative PCR assays

Total RNA was extracted from cells with RNAiso Plus reagent (cat. no. 9109; Takara Bio, Inc.) and cDNA was reverse-transcribed using the PrimeScript RT reagent kit (cat. no. RR047A; Takara Bio, Inc.) according to the manufacturer\'s instructions. The temperature protocol was as follows: 37°C for 15 min and 85°C for 5 sec for one cycle. Quantitative PCR analysis was performed using the One Step TB Green^®^ PrimeScript™ PLUS RT-PCR kit (Perfect Real Time) (cat. no. RR096A; Takara Bio, Inc.), with a 7500 Fast Real-Time RCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 95°C for 5 sec, 55°C for 30 sec, 72°C for 30 sec and repeats for 40 cycles. Each measurement was performed in triplicate and the results were normalized to the GAPDH internal control. The 2^−ΔΔCq^ method was used to calculate the relative expression levels of target genes ([@b19-ol-0-0-11830]). All primer sequences are presented in [Table SI](#SD1-ol-0-0-11830){ref-type="supplementary-material"}.

### Statistical analysis

Statistical analyses were conducted using SPSS version 19.0 software (IBM Corp.). All experiments were performed in triplicate and numerical data are presented as the mean ± standard deviation. Differences among PCa and normal prostate cells were analyzed by one-way ANOVA, and the Dunnett test was used as the post hoc test. Kaplan-Meier curves and the log-rank tests were used to assess associations between PCaSig expression and BCR. Cox proportional hazards analysis was performed to assess the relative impacts of different groups (high vs. low level) on BCR. The concordance index (C-index) was used to evaluate the discriminatory powers of the signature. And calibration plot was used as an internal validation of the nomogram. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Differential gene expression profiles

A total of 1,307 DEGs between the GS=6 and GS ≥7 groups were identified in the TCGA discovery cohort, according to the cut-off points of P\<0.05 and \|log2(FC)\|\>1.0. Among these, 869 were upregulated and 438 were downregulated ([Fig. 2](#f2-ol-0-0-11830){ref-type="fig"}).

### Development and validation of the PCasig

The clinicopathological characteristics in both the discovery and validation cohorts are presented in [Table SII](#SD1-ol-0-0-11830){ref-type="supplementary-material"}. The mean follow-up time was 31.4 months (range, 1.0--167.5 months) and 43.0 months (range 1.4--126.0 months), respectively. Among the 1,307 DEGs, 171 prognostic genes were identified using univariate Cox regression analysis in TCGA cohort, while 39 prognostic genes were identified by LASSO Cox using 10-fold cross-validation with minimum criteria ([Fig. 3](#f3-ol-0-0-11830){ref-type="fig"}).

A total of 10 prognostic genes, including potassium calcium-activated channel subfamily U member 1 (KCNU1), semenogelin 2 (SEMG2), SRY-box transcription factor 11 (SOX11), potassium inwardly rectifying channel subfamily J member 16 (KCNJ16), α-fetoprotein (AFP), guanylate cyclase 1 soluble subunit β 2 (GUCY1B2), transcription factor AP-2 β (TFAP2B), glutamate ionotropic receptor AMPA type subunit 4 (GRIA4), synaptonemal complex central element protein 1 (SYCE1) and neurexophilin 1 (NXPH1), were identified by multivariate Cox regression analysis ([Fig. 4A](#f4-ol-0-0-11830){ref-type="fig"}).

SEMG2, KCNJ16, TFAP2B, SYCE1 and KCNU1 were associated with a hazard ratio (HR) \<1. By contrast, AFP, GUCY1B2, GRIA4, NXPH1 and SOX11 had a HR \>1. The differential expression of the 10 prognostic genes between patients with GS=6 and patients with GS ≥7 is presented as a heatmap ([Fig. S1](#SD1-ol-0-0-11830){ref-type="supplementary-material"}).

The AUC for the PCasig was 0.791 and 0.835 for 3- and 5-year BCR-free survival, respectively ([Fig. 4B](#f4-ol-0-0-11830){ref-type="fig"}). The PCasig had a C-index of 0.78 (95% CI, 0.728--0.826).

The risk score for each patient was calculated as follows: (−0.16× SEMG2 expression level) + (−0.25× KCNJ16 expression level) + (−0.321× TFAP2B expression level) + (−0.14× SYCE1 expression level) + (−0.23× KCNU1 expression level) + (0.19× AFP expression level) + (0.17× GUCY1B2 expression level) + (0.20× GRIA4 expression level) + (0.22× NXPH1 expression level) + (0.30× SOX11 expression level). A total of 377 patients with GS ≥7 were divided into a high and a low-score group based on the median of the score distribution. This stratification of the risk score was associated with a hazard ratio (HR) of 5.18 (high vs. low; 95% CI, 3.241--8.272; P\<0.0001; [Fig. 4C](#f4-ol-0-0-11830){ref-type="fig"}).

In the validation cohort, the PCasig identified patients with a high-risk of BCR with an AUC of 0.761 for 5-year BCR-free survival time ([Fig. 5A](#f5-ol-0-0-11830){ref-type="fig"}) and a C-index of 0.66. The BCR risk of GS ≥7 patients in the high-score group was significantly higher compared with that in the low-score group (HR, 2.78; 95% CI, 1.39--5.54; P=0.0037; [Fig. 5B](#f5-ol-0-0-11830){ref-type="fig"}).

### Association and comparison of the PCasig with clinicopathological parameters

PCasig and clinicopathological parameters were analyzed using univariate and multivariate Cox regression analysis ([Tables I](#tI-ol-0-0-11830){ref-type="table"} and [SIII](#SD1-ol-0-0-11830){ref-type="supplementary-material"}). Regarding the PH Assumption, the P-value of seven factors, including age, GS, T, stage, N stage, Clinical M, residual tumor and the PCasig, was \>0.05 and the PH assumption could not be considered violated. The PCasig, GS and T stage were identified as independent predictors of BCR following RP in patients with GS ≥7.

A clinical nomogram was constructed based on the GS and T stage ([Fig. 6A](#f6-ol-0-0-11830){ref-type="fig"}). The AUCs at the 3- and 5-year BCR-free survival time points were 0.726 and 0.764, respectively ([Fig. 6B](#f6-ol-0-0-11830){ref-type="fig"}). The C-index of the nomogram was 0.713 (95% CI, 0.654--0.772). The BCR of patients with GS ≥7 in the high risk score group was significantly higher, compared with that of patients in the low score group (HR, 4.15; 95% CI, 2.56--64; P\<0.001; [Fig. 6C](#f6-ol-0-0-11830){ref-type="fig"}).

### Incremental predictive value of the PCasig for the clinical nomogram

A new nomogram was constructed and included the risk score, in addition to GS and T stage ([Fig. 7A](#f7-ol-0-0-11830){ref-type="fig"}). With the PCasig, the new nomogram yielded an AUC of 0.826 at the 3-year BCR-free survival time point, and 0.871 at the 5-year time point ([Fig. 7B](#f7-ol-0-0-11830){ref-type="fig"}). The C-index was 0.78 (95% CI, 0.734--0.829). The BCR risk of patients with GS ≥7 in the high risk score group was significantly higher compared with that of patients in the low score group (HR, 7.25; 95% CI, 4.54--11.56; P\<0.0001; [Fig. 7C](#f7-ol-0-0-11830){ref-type="fig"}). The BCR-free survival rate predicted using the new nomogram was positively associated with the actual observed rate ([Fig. 8A and B](#f8-ol-0-0-11830){ref-type="fig"}).

The NRI (NRI, 0.75; P\<0.0001, event NRI, 0.66; non-event NRI, 0.09) indicated that the performance was significantly improved after the integration of the PCasig into the clinical nomogram. For patients with BCR, the proportion of reclassification significantly increased by 0.66 (P\<0.001), indicating an improvement of 66% with the incorporation of the PCasig. For BCR-free patients, the proportion of reclassification significantly increased by 0.09 (P\<0.001), indicating an improvement of 9% ([Fig. S2](#SD1-ol-0-0-11830){ref-type="supplementary-material"}).

### Prognostic effect of the risk score in different GS subgroups

When limiting the univariate and multivariate analyses to patients with GS=7 in the discovery cohort, the PCasig remained the most significant predictor of BCR compared with the other clinicopathological parameters analyzed in the present study (HR, 9.29; 95% CI, 2.08--41.30; P=0.0034; [Table II](#tII-ol-0-0-11830){ref-type="table"}). Additionally, as indicated in [Table III](#tIII-ol-0-0-11830){ref-type="table"}, the PCasig remained the most significant predictor of BCR in the GS ≥8 subgroup (HR, 3.01; 95% CI, 1.58--5.75; P=0.0008).

The PCasig was used to divide patients with GS=7 (n=201) in the discovery cohort into low- and high-risk groups with a significant BCR difference (high vs. low; HR, 12.88; 95% CI, 4.981--33.32; P\<0.0001) with a C-index of 0.77 ([Fig. 8C](#f8-ol-0-0-11830){ref-type="fig"}). The PCasig was also used to divide patients with GS ≥8 into low and high-risk groups, which had a significantly different BCR risk (high vs. low; HR, 3.0; 95% CI, 1.742--5.126; P=0.0004) with a C-index of 0.63 ([Fig. 8D](#f8-ol-0-0-11830){ref-type="fig"}).

### Functional enrichment analysis

A total of 17 GO terms, including biological processes, cellular components and molecular functions, and five KEGG signaling pathways were enriched for the 9 mRNAs, as indicated in [Table SIV](#SD1-ol-0-0-11830){ref-type="supplementary-material"}. GO terms and KEGG pathway analysis demonstrated that the 9 mRNAs associated gene sets regulated 'transmembrane receptor protein serine/threonine kinase signaling pathway', 'BMP signaling pathway', 'cation channel complex' and 'ion channel complex', 'RNA polymerase II core promoter sequence-specific DNA binding', 'RNA polymerase II transcription coactivator activity', 'nicotine addiction and amphetamine addiction'.

### Expression of the genes analyzed in PCa and normal prostate cell lines

To verify whether the genes identified in the PCasig might be involved in PCa oncogenesis, the endogenous mRNA expression of all 9 genes was measured in five tumor-derived PCa cell lines (PC-3, DU145, 22RV1, LNCaP and C4-2) and a normal prostate cell line (RWPE-1) by quantitative PCR analysis. The results demonstrated that these genes exhibited relatively different expression in PCa cells compared with in normal prostate cell lines ([Fig. 9](#f9-ol-0-0-11830){ref-type="fig"}).

Discussion
==========

BCR prognostic tools are essential for the improvement of current treatment options for PCa and to reduce PCa-associated mortality for patients experiencing BCR following RP ([@b5-ol-0-0-11830]). Although previous studies have identified numerous potential biomarkers associated with prognosis and PCa progression, few of these markers have been applied in a clinical setting ([@b20-ol-0-0-11830]).

In the present study, the PCasig was developed using Cox regression and LASSO Cox analyses for the individualized prediction of BCR in patients with GS ≥7 from a TCGA dataset and validated in an Oncomine cohort. The PCasig consisted of 10 genes, including SEMG2, SOX11, AFP, KCNJ16, TFAP2B, SYCE1, KCNU1, GUCY1B2, GRIA4 and NXPH1. The signature may be used to classify patients with PCa into groups with low- and high-risk of BCR, which had significant differences in 3- and 5-year BCR-free survival time, with AUCs of 0.826 and 0.871, respectively. These results suggested that the PCasig could serve as a predictor of BCR-free survival. Additionally, a clinical nomogram was constructed for comparison with the PCasig in the TCGA cohort, revealing improved performance of the clinical nomogram after incorporation of the PCasig (the PCasig vs. clinical nomogram; AUC, 0.835 vs. 0.764; C-index: 0.777 vs. 0.713). To assess the independence of the PCasig in predicting BCR-free survival, univariate and multivariate Cox regression analyses were performed and the risk scores of patients based on the PCasig maintained a good association with BCR-free survival. The PCasig was combined with clinicopathological data to construct a nomogram to predict BCR after RP. Incorporating the PCasig and clinical factors into the nomogram significantly improved the performance of the clinical nomogram in predicting BCR after RP, facilitating the construction of an individualized treatment for BCR after RP. The NRI (NRI, 0.75; P\<0.001, event NRI, 0.66; non-event NRI, 0.09) indicated that performance was significantly improved following the integration of the PCasig into the clinical nomogram. The subgroup analysis further indicated a good prognostic value of the PCasig, regardless of GS. In addition, the endogenous mRNA expression of genes in the PCasig were measured in PCa cell lines and normal prostate cells, providing a basis for further functional studies on the role of these genes in PCa. Overall, the present findings highlighted the added value of the PCasig for the prediction of BCR in patients with PCa.

Previous studies have investigated the functional role of the 10 genes in the PCasig in cancer progression. For example, SEMG2 has been previously identified as a biomarker for lung cancer ([@b21-ol-0-0-11830]). SOX11 acts as a transcriptional regulator after forming a protein complex with other proteins. SOX11 overexpression can suppress proliferation, invasion and migration of PCa cells *in vitro* ([@b22-ol-0-0-11830]). AFP is a major plasma protein produced by the yolk sac and the liver during fetal life. The aberrant expression in adults is often associated with hepatoma or teratoma ([@b23-ol-0-0-11830]). It has been previously reported that AFP is negatively regulated by AT-binding transcription factor 1 (ATBF1) ([@b24-ol-0-0-11830]). Sun *et al* ([@b25-ol-0-0-11830]), reported that loss of ATBF1 is one mechanism that defines the progression in PCa. KCNJ16 is a potassium channel gene, which functions in fluid and pH balance regulation. Downregulation of KCNJ16 may lead to an imbalance in ion concentration between the extracellular and intracellular compartments, and influence tumor progression through multiple paths, including cell adhesion or migration, angiogenesis and apoptosis ([@b26-ol-0-0-11830]). TFAP2B transcription factor is a member of the AP-2 family, which serves an important role in cell apoptosis and autophagy ([@b27-ol-0-0-11830]). TFAP2B is also detectable in endometrial cancer, and patients with low TFAP2B expression have a worse prognosis compared with patients with high TFAP2B expression ([@b28-ol-0-0-11830]). SYCE1 consists of two lateral elements and a central region formed by transverse elements and a central element. In addition, SYCE1 may interact with chromosome 14 open reading frame 39 serving a role in the early stages of meiosis and the cell cycle ([@b29-ol-0-0-11830]). Furthermore, it has been suggested that SYCE1 may be a promising immunotherapy approach for lung adenocarcinoma ([@b30-ol-0-0-11830]). The potassium voltage-gated ion channel KCNU1 is regulated by calcium ion levels, which is critical for human fertility ([@b31-ol-0-0-11830]). KCNU1 may be activated by both intracellular pH and membrane voltage that mediates the export of K^+^ ([@b32-ol-0-0-11830]). GUCY1B2 is considered a pseudogene with a frameshift mutation on the Genbank website (<https://cipotato.org/genebankcip/>) and its role in PCa is not yet fully understood ([@b33-ol-0-0-11830]). Excitatory neurotransmitter receptor GRIA4 has been identified as a biomarker for colorectal cancer, which may vary in signal transduction properties ([@b34-ol-0-0-11830],[@b35-ol-0-0-11830]). NXPH1 functions as a secreted protein that promotes cell adhesion ([@b36-ol-0-0-11830]). High expression of NXPH1 is associated with poor prognosis in patients with breast cancer ([@b37-ol-0-0-11830]). Therefore, since these genes appear to serve several biological functions in multiple human malignancies, understanding the underlying role of each of these 10 genes in PCa would provide novel insights into the functional relevance of the PCasig.

However, there are some limitations in the present study. Firstly, since TCGA and Oncomine lack data regarding pre-surgical serum PSA, an association between PSA and BCR could not be determined. Secondly, future experimental studies should be conducted to examine the functional role of the genes identified in the present study and validate their expression at the protein level.

In conclusion, the present study identified a gene cluster that may act as an independent prognostic factor, or signature, with greater prognostic value for all patients regardless of GS, which can significantly improve the performance of clinical nomograms in predicting BCR of patients with PCa and GS ≥7.
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![LASSO Cox analysis via 10-fold cross-validation with minimum criteria. (A) Tuning parameter selection via 10-fold cross-validation with minimum criteria in the LASSO model. (B) LASSO coefficient profiles of 171 prognostic genes. LASSO, least absolute shrinkage and selection operator.](ol-20-03-2906-g02){#f3-ol-0-0-11830}

![Risk score performance in the training datasets. (A) Forest plot representing 10 genes identified as independent factors for BCR prediction using multivariate Cox analysis. (B) ROC curve based on the PCasig in the discovery cohort. (C) Kaplan-Meier curves of the PCasig in the discovery cohort to predict BCR-free survival. BCR, biochemical recurrence; AUC, area under the curve; ROC, receiver operating characteristic; HR, hazard ratio; C-index, concordance index.](ol-20-03-2906-g03){#f4-ol-0-0-11830}
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![Clinical nomogram constructed using the Gleason score and the American Joint Committee on Cancer T stage. (A) Clinical nomogram predicting survival probabilities of patients with 3- and 5-year BCR-free survival. (B) Receiver operating characteristic curve based on the clinical nomogram. (C) Kaplan-Meier curves based on the clinical nomogram were used for the prediction of BCR-free survival in the discovery cohort. BCR, biochemical recurrence; T, pathological T.](ol-20-03-2906-g05){#f6-ol-0-0-11830}

![Nomogram constructed using the risk score, Gleason score and the American Joint Committee on Cancer T stage. (A) Nomogram predicting survival probabilities of patients with 3- and 5-year BCR-free survival. (B) Receiver operating characteristic curve based on the new nomogram. (C) Kaplan-Meier curves based on the new nomogram were used to determine the association between the risk score and survival. BCR, biochemical recurrence; AUC, area under the curve; HR, hazard ratio; PT, pathological T; C-index, concordance index.](ol-20-03-2906-g06){#f7-ol-0-0-11830}

![Validation of the new nomogram in predicting overall survival of PCa in the TCGA cohort. Calibration curves of the new nomogram predicting BCR-free survival at (A) 3 and (B) 5 years. (C and D) Prognostic effect of risk score in different GS subgroups. (C) Kaplan-Meier analysis of BCR-free survival in the high-risk and low-risk subgroups within TCGA patient cohort with GS=7. (D) Kaplan-Meier analysis of patients with GS ≥8 in TCGA cohort. BCR, biochemical recurrence; HR, hazard ratio; TCGA, The Cancer Genome Atlas; C-index, concordance index.](ol-20-03-2906-g07){#f8-ol-0-0-11830}

![Endogenous expression of the 9 mRNAs. Expression of 9 mRNAs was measured using reverse transcription-quantitative PCR in five prostate cancer (PC-3, DU145, 22Rv1, LNCaP and C4-2) and one normal prostate (RWPE-1) cell lines. GAPDH was used as an internal reference. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. RWPE-1. (A) KCNU1, (B) SEMG2, (C) SOX11 (D) KCNJ16, (E) AFP, (F) TFAP2B, (G) GRIA4, (H) SYCE1, (I) NXPH1. ns, not significant; KCNU1, potassium calcium-activated channel subfamily U member 1; SEMG2, semenogelin 2; SOX11, SRY-box transcription factor 11; KCNJ16, potassium inwardly rectifying channel subfamily J member 16; AFP, α-fetoprotein; TFAP2B, transcription factor AP-2 β; GRIA4, glutamate ionotropic receptor AMPA type subunit 4; SYCE1, synaptonemal complex central element protein 1; NXPH1, neurexophilin 1.](ol-20-03-2906-g08){#f9-ol-0-0-11830}

###### 

Multivariate HR analysis for clinicopathological variables and risk score in The Cancer Genome Atlas cohort.

               Multivariate Cox 1     Multivariate Cox 2                                
  ------------ ---------------------- -------------------- ---------------------------- -----------
  GS                                                                                    
    3+4        1.00                                        1.00                         
    4+3        2.56 (0.87--7.51)      0.046                2.21 (0.77--6.36)            0.09200
    ≥8         3.97 (1.46--10.73)     0.0020               3.80 (1.45--9.93)            0.00650
  PT                                                                                    
    T2         1.00                                        1.00                         
    T3a        1.99 (0.77--5.08)      0.020                2.94 (1.18--7.25)            0.02000
    T3b + T4   2.84 (1.09--7.37)      0.0030               3.44 (1.40--8.48)            0.00700
  PN                                                                                    
    N0         1.00                                        1.00                         
    N1         135 (0--4.19×10^55^)   0.91                 120.00 (0.00--3.19×10^45^)   0.92000
    NX         0.47 (0.11--1.94)      0.29                 0.37 (0.11--1.04)            0.39000
  Risk score                                                                            
    Low        NA                                          1.00                         
    High       NA                                          3.34 (1.87--6.00)            \<0.00010

NA indicates that the variable was not analyzed using multivariate Cox analysis. The multivariate Cox 1 model adjusts for GS, PT and PN. Multivariate Cox 2 adjusts for GS, PT, PN and risk score. HR, hazard ratio; GS, Gleason score; PT, pathological tumor grade; PN, pathological lymph node grade; NX, patients did not undergo lymph node dissection.

###### 

Cox regression analysis for PCasig and clinicopathological variables in the GS=7 subgroup from The Cancer Genome Atlas dataset.

                   Univariate Cox             Multivariate Cox                        
  ---------------- -------------------------- ------------------ -------------------- ---------
  Age, years                                                                          
    ≤65            1.00                                          NA                   
    \>65           2.48 (0.88--7.00)          0.08500            NA                   
  PT                                                                                  
    T2             1.00                                          1.00                 
    T3a            5.20 (1.45--18.80)         0.01100            3.87 (1.04--14.30)   0.04300
    T3b + T4       4.40 (1.00--19.00)         0.05100            2.24 (0.41--12.10)   0.34000
  PN                                                                                  
    N0             1.00                                          1.00                 
    N1             6.22 (2.19--17.60)         \<0.00010          4.70 (1.33--16.80)   0.01600
    NX             8.20 (0.070--4.19)         0.56000            0.10 (0.11--6.43)    0.85000
  Clinical M                                                                          
    M0             1.00                                          NA                   
    M1             3.90×10^−8^ (0.00--2.43)   0.99000            NA                   
  Residual tumor                                                                      
    R0             1.00                                                               
    R1 or R2       0.50 (0.12--2.00)          0.36200            NA                   
    RX             3.30×10^−8^ (0.00--1.97)   0.99800            NA                   
  Risk score                                                                          
    Low            1.00                                          1.00                 
    High           13.00 (3.13--12.91)        \<0.00010          9.29 (2.08--41.30)   0.00340

N=201. NA indicates that the variable was not analyzed using multivariate Cox regression. HR, hazard ratio; GS, Gleason score; PT, pathological tumor grade; PN, pathological lymph node grade; pNX, patients did not undergo lymph node dissection; M, metastasis; R, residual tumor stage; RX, residual tumor not examined.

###### 

Cox regression analysis for PCasig and clinicopathological variables in the GS≥8 subgroup from The Cancer Genome Atlas dataset.

                   Univariate Cox       Multivariate Cox                        
  ---------------- -------------------- ------------------ -------------------- ---------
  Age, years                                                                    
    ≤65            1.00                                    NA                   
    \>65           0.90 (0.51--1.56)    0.71400            NA                   
  PT                                                                            
    T2             1.00                                    1.00                 
    T3a            2.23 (0.64--7.70)    0.01100            2.40 (0.69--8.40)    0.16000
    T3b+T4         3.88 (1.19--12.60)   0.02400            4.02 (1.20--13.10)   0.02100
  PN                                                                            
    N0             1.00                                    NA                   
    N1             0.98 (0.54--1.77)    0.95000            NA                   
    NX             0.29 (0.04--2.18)    0.23000            NA                   
  Clinical M                                                                    
    M0             1.00                                    NA                   
    M1             0.43 (0.050--3.15)   0.41000            NA                   
  Residual tumor                                                                
    R0             1.00                                    NA                   
    R1 or R2       1.59 (0.92--2.77)    0.09000            NA                   
    RX             0.24 (0.03--1.80)    0.17000            NA                   
  Risk score                                                                    
    Low            1.00                                    1.00                 
    High           3.00 (1.57--5.73)    0.00082            3.01 (1.58--5.75)    0.00080

N=176. NA indicates that the variable was not analyzed using multivariate Cox regression. HR, hazard ratio; GS, Gleason Score; PT, pathological tumor grade; PN, pathological lymph node grade; pNX, patients did not undergo lymph node dissection; M, metastasis; R, residual tumor stage; RX, residual tumor not examined.
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